ADULT Updated: May 6, 2020

Regimen Reference Order – pegylated liposomal DOXOrubicin

ARIA: GYNE - [doxorubicin (peg-liposomal)]

Planned Course: Every 28 days until disease progression or unacceptable toxicity

Indication for Use: Ovarian Cancer Recurrent

CVAD: At Provider's Discretion

Proceed with treatment if:

Cycle 1

ANC equal to or greater than 1.5 x $10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

Cycle 2 and onwards

ANC equal to or greater than 1.2 x $10^9/L$ AND Platelets equal to or greater than 75 x $10^9/L$

Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

| | Pre-treatment Requirements | | | | |
|----------------|----------------------------|------|-------------------------------|--|--|
| | Drug | Dose | CCMB Administration Guideline | | |
| Not Applicable | | | | | |

| Establish primary solution 500 mL of: D5W (incompatible with normal saline) | | | | |
|---|----------------------|--|--|--|
| Drug | Dose | CCMB Administration Guideline | | |
| dexamethasone | 8 mg | Orally 30 minutes pre-chemotherapy | | |
| pegylated liposomal DOXOrubicin | 40 mg/m ² | IV in D5W 250 mL over 90 minutes OR IV in D5W 500 mL over 2 hours if dose is greater than or equal t 90 mg (Maximum rate 1 mg/minute) If no reaction, subsequent doses may be administered over 60 minutes | | |

Flush after each medication:

• 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'



REQUIRED MONITORING

All Cycles

- CBC, serum creatinine and liver enzymes as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

| | Recommended Support Medications | | |
|---|---------------------------------|------------|--|
| l | Drug | Dose | CCMB Administration Guideline |
| | metoclopramide | 10 – 20 mg | Orally every 4 hours as needed for nausea and vomiting |

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

· Not applicable

